UNMASK THE FACTS

September 20 - October 3

September 20, 2021

Pfizer releases trial results of COVID-19 vaccine for kids

Pfizer and BioNTech said that clinical trial results of their pediatric COVID-19 vaccine showed encouraging outcomes in volunteers. The data shows a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years old. The trial uses a two-dose regimen of a smaller dose (10 μ g) administered 21 days apart. The company will seek FDA authorization as soon as possible.

READ MORE >

September 30, 2021

More parents in the U.S. are wanting to get their kids vaccinated against COVID-19

According to a new Kaiser Foundation poll, about a third of parents (34%) whose children are 5 to 11 years old say they want their child to get vaccinated against COVID-19 right away (up slightly from July). Another third (32%) want to wait and see. One in four (24%) parents said they would definitely not vaccinate their children against COVID-19.

READ MORE >

September 24, 2021

Pfizer booster shots authorized for older adults and high-risk populations

The CDC recommends that people who are 65+ years old, residents in long-term care facilities, or 50-64 years old with certain underlying medical conditions should get a booster of Pfizer vaccine at least six months after completing their Pfizer primary COVID-19 vaccine series. Younger people (18-49 years old) with certain underlying medical conditions, and people aged 18-64 years who are at increased risk of COVID-19 exposure and transmission may get a booster based on their individual benefits and risks.

READ MORE >

September 21, 2021

J&J booster shot provides 12-fold increase in antibodies

New data from Johnson & Johnson showed that protection against COVID-19 increases when a booster shot of the Janssen vaccine is administered. The company announced that when a booster of their COVID-19 vaccine was given six months after the single shot, antibody levels increased 9-fold one week after the booster and continued to climb to 12-fold higher four weeks after the booster. J&J is currently seeking FDA's authorization for a booster shot. The FDA will review this data later next week.

READ MORE

October 1, 2021

New antiviral pill could help protect against COVID-19 hospitalization and death

Early studies of Merck & Co's experimental oral COVID-19 antiviral drug, molnupiravir, show the pill to be effective against known variants of the coronavirus. The investigational medicine significantly reduced the risk of hospitalization or death in the trials. At the interim analysis, the antiviral reduced the risk of hospitalization or death by approximately 50%.

READ MORE >



Disclaimer: This project was funded in whole by a cooperative agreement with the Centers for Disease Control and Prevention grant number NU50CK000588. The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this resource center do not necessarily represent the policy of CDC or HHS and should not be considered an endorsement be Federal Government.